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Introduction
Herpes viral infection in humans includes both 
herpes simplex (HSV) and herpes zoster. The varicella 
zoster virus (VZV) is the etiology of both primary 
varicella and herpes zoster (commonly known as 
chicken pox and shingles, respectively), with herpes 
zoster being the re-activated form of the virus. The 
classical presentation of herpes zoster is a unilateral 
distribution of vesicles along a single or adjacent 
dermatome [1]. Disseminated herpes zoster is 
defined as having more than 20 lesions outside the 
primary or adjacent dermatome [2].
Although uncommon among all herpes zoster 
infections, the prevalence of disseminated VZV in 
a setting of immunosuppression is thought to be 
anywhere from 10 to 40% [3, 4]. VZV is the most 
frequent infection seen in allogeneic bone marrow 
transplant recipients [5]. Immunosuppressed 
individuals are at risk for complications such as 
encephalitis, hepatitis, and pneumonitis owing to the 
possibility of visceral dissemination. Clinical suspicion 
for disseminated zoster should extend beyond the 
presence of cutaneous lesions. Abdominal zoster can 
present with severe abdominal pain up to two weeks 
prior to the development of skin vesicles [5]. Delayed 
diagnosis leads to high mortality rates despite 
antiviral therapy. A woman who recently initiated 
chemotherapy for breast cancer and subsequently 
developed disseminated cutaneous herpes zoster 
without dermatomal skin lesions is described.
Case Synopsis: A 63-year-old woman was diagnosed 
with left T2N0 breast cancer. Within one month of 
diagnosis, she began cycle 1 of doxorubicin and 
cyclophosphamide chemotherapy. Ten days after 
starting chemotherapy, she developed painful and 
Abstract
Disseminated herpes zoster is defined as the presence 
of more than 20 lesions outside the dermatome. 
This unusual presentation is more common in 
immunosuppressed patients. Complications such 
as hepatitis, encephalitis, and pneumonitis are more 
likely in individuals with disseminated varicella zoster 
virus infection.
A 63-year-old woman being treated for breast cancer 
developed multiple pustules and vesicles days 
after starting doxorubicin and cyclophosphamide 
chemotherapy. Ten individual lesions appeared on 
her chest, abdomen, back, and leg. Non-dermatomal 
disseminated herpes zoster was suspected. She was 
treated with oral antiviral therapy, as well as with oral 
and topical antibiotics. Varicella zoster virus infection 
was confirmed by direct fluorescent antibody staining. 
After one month, her skin lesions had resolved and 
she resumed chemotherapy.
In a setting of immunosuppression, the rare 
presentation of disseminated herpes zoster without 
dermatome should be considered. Appropriate 
antiviral therapy should be administered while waiting 
for confirmation of the diagnosis, so as to reduce the 
risk of visceral dissemination of the varicella zoster 
virus infection.
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pruritic lesions on her chest, abdomen, back, and 
right leg; neither central nervous system, hepatic, 
nor pulmonary symptoms were present. When she 
presented to her oncologist, her chemotherapy was 
discontinued and she was referred to a dermatologist 
for evaluation and treatment.
Cutaneous examination revealed lesions that were 
distributed across the patient’s body without any 
dermatomal pattern. The widespread individual 
pustules with surrounding erythema were located on 
her chest, abdomen, and back (Figures 1, 2). She also 
had large erosions on her right knee and posterior 
right leg (Figures 3, 4).
Because the patient had a history of chicken pox as 
a child, the possibility of primary varicella was ruled 
out. The differential diagnosis included disseminated 
herpes simplex and disseminated herpes zoster. 
A direct fluorescent antibody (DFA) staining was 
performed on the material obtained after removing 
the roof of a blister and scraping its base with 
a #15 blade. Results from DFA were positive for 
herpes zoster virus and negative for herpes simplex 
virus, thus confirming a diagnosis of disseminated 
cutaneous herpes zoster virus infection.	
	
	
	
Figure 1. A view of the back of a 63-year-old woman who 
developed widespread pustules within ten days after starting 
chemotherapy for treatment of breast cancer. Lesions are seen 
bilaterally and across multiple dermatomes. Closer inspection 
revealed individual pustules on an erythematous base. The lesions 
were painful and pruritic.
	
	
	
	
Figure 2. The chest and abdomen also show widespread skin 
lesions without any dermatomal pattern.
	
	
	
	
Figure 4. View of additional pustules on the patient’s right knee 
of disseminated cutaneous herpes zoster without dermatomal 
skin lesions.
	
	
	
	
Figure 3. A view of several large pustules noted on the patient’s 
right posterior thigh.
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Therapeutic intervention was initiated: a ten-day 
course of oral valacyclovir (one gram three times 
daily) and cefdinir (300 mg orally twice daily) to treat 
possible bacterial impetiginization of the lesions. 
Topical treatment of her lesions included dilute 
vinegar soaks (one part white vinegar and four 
parts water) twice a day followed by application of 
mupirocin 2% ointment. At follow-up examination 
by the dermatologist one week later, the patient was 
clinically improved. There were no new vesicles or 
pustules and her existing lesions were crusted and 
no longer painful.
The patient completed the ten-day courses of 
valacyclovir and cefdinir; she continued the vinegar 
soaks until her oncology appointment two weeks 
later. Her oncologist noted that all of her lesions were 
nearly resolved and none of them were painful. Given 
the successful management of the varicella zoster 
virus infection, she was able to begin her second 
cycle of chemotherapy.
Case Discussion
Herpes zoster, commonly known as shingles, is the 
re-activated form of the varicella zoster virus. It is 
most prevalent in people over the age of 50 with the 
lifetime risk of herpes zoster shown to be 20% [6]. The 
classic clinical presentation of herpes zoster is several 
days of severe pain within the affected dermatome, 
followed by an eruption of unilateral dermatomal 
skin lesions. This characteristic presentation of the 
infection often allows for a diagnosis to be made 
solely on a clinical basis.
However, in patients who develop cutaneous 
disseminated herpes zoster infection without 
dermatomal skin lesions, the diagnosis is not as 
readily apparent. Dissemination of VZV infection 
occurs primarily in immunocompromised individuals 
and is defined as having greater than 20 lesions 
outside the primary or adjacent dermatomes. Rarely, 
as in our patient, disseminated cutaneous herpes 
zoster can occur with an absence of skin lesions in a 
dermatome.
A Tzanck smear is a quick, inexpensive way to confirm 
a herpes infection, but it cannot distinguish between 
herpes simplex and herpes zoster. However, it can 
easily be performed in the office or at the bedside 
to allow for rapid initiation of antiviral therapy. A 
scraping to obtain epidermal cells from the base or 
underside of the roof of one of the blisters will show 
the multinucleated giant cells characteristic of herpes 
viral infection. The Tzanck smear is positive in 75% of 
VZV cases [7, 8].
When the possibility of herpes simplex and herpes 
zoster are both in the clinical differential diagnosis, 
direct fluorescent antibody (DFA) or polymerase chain 
reaction (PCR) can be conducted for confirmation. 
DFA is performed by scraping the base of the lesion 
with a #15 blade without causing bleeding. The 
obtained material on the tip of the blade is applied 
to the glass microscope slides to be submitted for 
testing. A negative DFA cannot rule out herpes zoster 
owing to its low sensitivity and additional testing is 
necessary. PCR has significantly higher sensitivity 
than DFA, but a positive result for either test is 
diagnostically definitive [9].
Prompt treatment is required if disseminated herpes 
zoster infection is suspected, particularly in the 
setting of immunosuppression. Progression from 
cutaneous dissemination to visceral involvement of 
the brain, lungs, or liver can be seen in up to 10% of 
immunocompromised individuals [5]. Because the 
antiviral dosage for treating herpes zoster is at least 
twice that of herpes simplex, conservative treatment 
Table 1. Antiviral therapy dosages for primary episode of herpes zoster versus herpes simplex [9, 10].
Therapy Dosing for herpes zoster [10] Dosing for herpes simplex [9]
Oral acyclovir 800 mg PO 5x/day for 7-10 days 200 mg PO 5x/day for 10 days
Valacyclovir 1 g PO q8h for 7 days 500 mg PO q12h for 10 days
Acyclovir IV 10 mg/kg q8h IV 5 mg/kg q8h IV for 10 days
 
Abbreviations: h: hour; kg: kilogram; mg: milligram; PO: by mouth; q: every
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with a higher antiviral dose is recommended prior to 
diagnostic confirmation of herpes zoster or herpes 
simplex (Table 1), [10, 11]. In a hospital setting, 
intravenous acyclovir is shown to shorten the course 
of cutaneous VZV, as well as to reduce the risk of 
visceral dissemination [1, 12].
Historically, acyclovir has been the drug of choice for 
herpes zoster therapy, but valacylovir has become 
more commonly used owing to its increased 
bioavailiability, and thus its greater effectiveness in 
preventing new lesions and reducing time to healing 
for existing lesions [10, 13]. Additionally, valacyclovir 
has been shown to be effective in reducing the 
duration of postherpetic neuralgia [14]. Antiviral 
therapy is most effective if initiated within 72 hours of 
viral onset, underlining the need for rapid diagnosis 
and treatment of suspected disseminated herpes 
zoster [15].
The progression of the herpes zoster virus skin lesions 
from erythematous macules and papules to vesicles 
to crusts occurs in about two weeks. Postherpetic 
neuralgia (PHN) is the most common residual 
symptom following infection of herpes zoster and 
immunocompromised individuals are thought to 
be at greater risk for developing PHN [16]. Rates of 
herpes zoster recurrence in immunocompromised 
patients eight years after the initial episode are as 
high as 12% [17]. In our patient, disseminated herpes 
virus infection was suspected after examination of 
her cutaneous lesions; antiviral therapy (empirically 
treated with valacyclovir at a dose appropriate for 
herpes zoster virus infection) was promptly initiated, 
allowing for rapid resolution of her lesions without 
development of PHN.
Conclusion
Our patient exhibited painful pustular lesions 
without any dermatomal pattern. Her chemotherapy-
induced immunosuppression made disseminated 
herpes virus infection a likely possibility. The 
differential diagnosis included cutaneous lesions of 
either disseminated herpes simplex or disseminated 
herpes zoster (without dermatome skin lesions). She 
was promptly started on oral valacyclovir as antiviral 
therapy and the diagnosis of herpes zoster was 
confirmed by a positive DFA. Her lesions resolved 
within a few weeks and she had no residual pain 
following the infection. Disseminated herpes zoster 
should be included in the differential diagnosis if 
there are multiple vesicles and pustules, even in the 
absence of dermatomal skin lesions, in a setting of 
immunosuppression. Consideration of disseminated 
herpes zoster allows for prompt treatment, thereby 
reducing the risk of serious complications related 
to visceral dissemination, as well as improving the 
prognosis for the patient.
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